Axsome Therapeutics, Inc. AXSM
As ofNov 16, 2026, 2:30 PM EST
- YTD
- -24.28%
- 1 year
- -1.00%
- Market cap
- 7.27B
- Revenue (ttm)
- 865.27M
- Profit margin
- -18.18%
- EPS (ttm)
- -3.03
- Shares out
- 52.60M
- Forward P/E
- 41.91
- YTD return
- -24.28%
- 1-year return
- -1.00%
- 50-day average
- 172.78
- 200-day average
- 197.26
- Volume
- 341.69K
- Avg volume
- 853.50K
- Open
- 141.25
- Previous close
- 141.69
- Day's range
- 136.33 – 141.70
- 52-week range
- 123.00 – 260.19
- Beta
- 0.83
- Analysts
- Strong Buy
- Price target
- 265.86 (+92.2%)
- Earnings date
- Feb 22, 2027
5D +9.05 (+6.82%)
Key statistics
- Enterprise value
- 7.50B
- Price / sales
- 8.61
- Price / book
- 70.67
- Revenue growth
- 51.90%
- Free cash flow
- -24.38M
- Total cash
- 313.86M
- Total debt
- 224.22M
- Return on equity
- -175.59%
- Short % of float
- 9.60%
Fundamental scorecard
8 of 25 checks passed on AXSM’s reported financials
8of 25 checks passed
- Value 2 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 220.00
- Target (mean)
- 265.86
- Target (high)
- 315.00
- Strong buy3
- Buy18
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 22, 2027
Expected Feb 22, 2027. Consensus EPS estimate -0.11198.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 22, 2027 | Dec 30, 2026 | -0.0479 | — | — | — |
| Nov 2, 2026 | Sep 30, 2026 | -0.63425 | -0.25 | +0.38 | +60.58% |
| Aug 10, 2026 | Jun 30, 2026 | -0.89205 | -0.99 | -0.10 | -10.98% |
| May 4, 2026 | Mar 31, 2026 | -0.85 | -1.26 | -0.41 | -48.24% |
| Feb 23, 2026 | Dec 31, 2025 | -0.70 | -0.71 | -0.01 | -1.43% |
| Nov 3, 2025 | Sep 30, 2025 | -0.82 | -0.94 | -0.12 | -14.63% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 13, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Nov 4, 2026 | Mizuho | main | Outperform | Outperform |
| Nov 3, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Nov 3, 2026 | UBS | main | Buy | Buy |
| Nov 3, 2026 | RBC Capital | main | Outperform | Outperform |
| Nov 3, 2026 | Guggenheim | main | Buy | Buy |
About Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase II trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. It has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation treatment. The company was incorporated in 2012 and is based in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- axsome.com
News
Axsome Therapeutics Sees AUVELITY Prescription Surge After Alzheimer's Agitation Launch
Axsome Therapeutics, Inc. (AXSM) Presents at UBS Global Biopharma Conference 2026 Transcript
Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027? Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Lowers Price Target to $223
Nasdaq Sell-Off: 2 Stocks to Buy on the Dip and Hold for 5 Years
Axsome Therapeutics Tops $1 Billion Revenue Run Rate as AUVELITY Sales Surge
Axsome Therapeutics, Inc. (AXSM) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript Mizuho Maintains Outperform on Axsome Therapeutics, Lowers Price Target to $272
Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $249
UBS Maintains Buy on Axsome Therapeutics, Lowers Price Target to $239
Your note
Sign in to keep a note on AXSM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COLEMAN MARK H | Director | Sale | Jun 9, 2026 | 434,245 |
| JACOBSON MARK L | Chief Operating Officer | Sale | Sep 2, 2026 | 0 |
| JEFFS ROGER A | Director | Sale | Jun 10, 2026 | 58,367 |
| MAHONY SUSAN M | Director | Sale | Jun 9, 2026 | 829 |
| MAIZEL ARI | Officer | Sale | Apr 21, 2026 | 0 |
| MURDOCK HUNTER R | General Counsel | Sale | Jun 22, 2025 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 5.90% | 3,103,708 | 439.76M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 3.77% | 1,983,514 | 281.04M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.74% | 1,965,086 | 278.43M | Jun 29, 2026 |
| Invesco Ltd. | 3.18% | 1,671,684 | 236.86M | Jun 29, 2026 |
| FMR, LLC | 2.93% | 1,539,163 | 218.08M | Jun 29, 2026 |
| Geode Capital Management, LLC | 1.92% | 1,010,373 | 143.16M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.64% | 1,388,721 | 196.77M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.91% | 1,003,488 | 142.18M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.10% | 578,233 | 81.93M | Jun 29, 2026 |
| AIM Counselor Series TRT -Invesco Discovery Fd. | 1.02% | 535,275 | 75.84M | Aug 30, 2026 |
| Vanguard Explorer Fund | 1.01% | 531,004 | 75.24M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.94% | 495,762 | 70.24M | Jun 29, 2026 |
